Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma

Acta Oncol. 2020 Dec;59(12):1547-1551. doi: 10.1080/0284186X.2020.1821913. Epub 2020 Sep 24.

Michael Asger Andersen^{1

2}, Rebecca Valentin^{1

3}, Lene Dissing Sjö⁴, Line Borgwardt⁵, Kjeld Schmiegelow^{6

7}, Mette Klarskov Andersen^{4

8}, Rasmus L Marvig⁵, Christina Westmose Yde⁵, Carsten Utoft Niemann¹

¹ Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
² Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
³ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁴ Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
⁵ Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
⁶ Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Copenhagen, Denmark.
⁷ Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark.
⁸ Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

No abstract available

Publication types